SEMR vs GLPG Comparison

SEMrush Holdings Inc offers an online visibility management software-as-a-service (SaaS) platform enabling its clients globally to identify and reach the right audience for their content. The platform utilizes data and intelligence at the core, surrounded by AI-powered interconnected hubs to provide customers with key data, helping them understand trends and derive actionable insights to improve their websites and social media pages, and distribute relevant content to their targeted customers across a variety of digital channels. The company generates nearly all of its revenue from subscriptions to its online visibility management SaaS platform under a SaaS model. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other regions.

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.